Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 2Afrezza
02 4Human Insulins
03 3Humulin
04 5Insuman
05 1Levemir
06 1Modern Insulins (Insulin analogues)
07 1New-Generation Insulin
08 2New-generation Insulin
09 1NovoMix/ NovoLog Mix
10 1NovoRapid/NovoLog
11 1Total Modern Insulins
12 5Xultophy
Main Therapeutic Indication : Diabetes
Currency : USD
2014 Revenue in Millions : 3.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Diabetes
Currency : USD
2015 Revenue in Millions : 151
2014 Revenue in Millions : 155
Growth (%) : 3%
Main Therapeutic Indication : Diabetes
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 8
Growth (%) : New Launch
Main Therapeutic Indication : Diabetes
Currency : USD
2016 Revenue in Millions : 137
2015 Revenue in Millions : 149
Growth (%) : -9
Main Therapeutic Indication : Diabetes
Currency : USD
2016 Revenue in Millions : Not Reported
2015 Revenue in Millions : 7
Growth (%) : -100
Main Therapeutic Indication : Diabetes
Currency : USD
2017 Revenue in Millions : 133
2016 Revenue in Millions : 160
Growth (%) : -17
Main Therapeutic Indication : Diabetes
Currency : USD
2018 Revenue in Millions : 0
2017 Revenue in Millions : 121
Growth (%) : -100%
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 398
2019 Revenue in Millions : 359
Growth (%) : 11
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 405
2020 Revenue in Millions : 391
Growth (%) : 9
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 410
2021 Revenue in Millions : 405
Growth (%) : 1
LOOKING FOR A SUPPLIER?